Literature DB >> 20606564

Allogeneic T-cell therapy for Epstein-Barr virus-positive posttransplant lymphoproliferative disease: long-term follow-up.

Tanzina Haque, Karen A McAulay, Deirdre Kelly, Dorothy H Crawford.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20606564     DOI： 10.1097/TP.0b013e3181d7c424

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  16 in total

Review 1.  Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.

Authors:  Lauren McLaughlin; C Russell Cruz; Catherine M Bollard
Journal:  Ther Adv Hematol       Date:  2015-12

2.  Immunotherapy for EBV-associated malignancies.

Authors:  Anna Merlo; Riccardo Turrini; Riccardo Dolcetti; Paola Zanovello; Antonio Rosato
Journal:  Int J Hematol       Date:  2011-02-19       Impact factor: 2.490

Review 3.  Posttransplant lymphoproliferative disease following liver transplantation.

Authors:  Kala Y Kamdar; Cliona M Rooney; Helen E Heslop
Journal:  Curr Opin Organ Transplant       Date:  2011-06       Impact factor: 2.640

Review 4.  EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target.

Authors:  Keri Toner; Catherine M Bollard
Journal:  Blood       Date:  2022-02-17       Impact factor: 22.113

Review 5.  T lymphocytes targeting native receptors.

Authors:  Cliona M Rooney; Ann M Leen; Juan F Vera; Helen E Heslop
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 6.  T cells for viral infections after allogeneic hematopoietic stem cell transplant.

Authors:  Catherine M Bollard; Helen E Heslop
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

7.  Moving Successful Virus-specific T-cell Therapy for Hematopoietic Stem Cell Recipients to Late Phase Clinical Trials.

Authors:  Cliona Rooney; Ann Leen
Journal:  Mol Ther Nucleic Acids       Date:  2012-11-13       Impact factor: 10.183

8.  Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.

Authors:  Mark A Vickers; Gwen M Wilkie; Nicolas Robinson; Nadja Rivera; Tanzina Haque; Dorothy H Crawford; Jacqueline Barry; Neil Fraser; David M Turner; Victoria Robertson; Phil Dyer; Peter Flanagan; Helen R Newlands; John Campbell; Marc L Turner
Journal:  Br J Haematol       Date:  2014-07-26       Impact factor: 6.998

9.  Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry.

Authors:  Britta Eiz-Vesper; Britta Maecker-Kolhoff; Rainer Blasczyk
Journal:  Front Immunol       Date:  2013-01-28       Impact factor: 7.561

10.  Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management.

Authors:  Marieke L Nijland; Marie José Kersten; Steven T Pals; Frederike J Bemelman; Ineke J M Ten Berge
Journal:  Transplant Direct       Date:  2015-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.